

## Quantifying hope: An EU perspective of rare disease therapeutic space and market dynamics

Emmanuelle Cacoub<sup>1,2</sup>, Nathalie Barreto Lefebvre<sup>1</sup>, Dimitrije Milunov<sup>1</sup>, Manish Sarkar<sup>1,\*</sup>, Soham Saha<sup>1,\*</sup>

<sup>1</sup> *Medinsights SAS, 8 rue Milton, 75009 Paris, France*

<sup>2</sup> *ESCP Business School, 3 Rue Armand Moisant, 75015 Paris, France*

**Author emails:** [emmanuelle.cacoub@medinsights.fr](mailto:emmanuelle.cacoub@medinsights.fr); [nathalie.lefebvre@medinsights.fr](mailto:nathalie.lefebvre@medinsights.fr); [dimitrije.milunov@medinsights.fr](mailto:dimitrije.milunov@medinsights.fr); [manish.sarkar@medinsights.fr](mailto:manish.sarkar@medinsights.fr); [soham.saha@medinsights.fr](mailto:soham.saha@medinsights.fr)

**\* Co-corresponding authors:**

*Soham Saha, Medinsights SAS, Paris, France, Email: [soham.saha@medinsights.fr](mailto:soham.saha@medinsights.fr)*

*Manish Sarkar, Medinsights SAS, Paris, France, Email: [manish.sarkar@medinsights.fr](mailto:manish.sarkar@medinsights.fr)*

**Summary:**

Rare diseases, affecting millions globally, pose a significant healthcare burden despite impacting a small population. While most are genetic and often begin in childhood, diagnosis remains slow and only 5% have approved treatments. The UN emphasizes improved access to primary care for these patients and their families. Whole-genome sequencing (WGS) and next-generation sequencing (NGS) offer hope for earlier and more accurate diagnoses, potentially leading to preventative measures and targeted therapies. This study explores the therapeutic landscape for rare diseases, analyzing drugs in development by 176 companies and those already approved by the European Medicines Agency (EMA). We differentiate between orphan drugs with market exclusivity and repurposed existing drugs, both crucial for patients. By analyzing market size, segmentation, and publicly available data, this comprehensive study aims to pave the way for improved treatments and a brighter future for rare disease patients.

**Funding:** This work received no external funding. External agencies or companies had no role in the idea and study design, model execution and evaluation, and drafting of figures and manuscript.

**Keywords:** Rare diseases, orphan drug designations, European Medicines Agency, market share, revenue model, pharmaceuticals, biotech, drug repurposing, external innovation

## Introduction

Rare diseases pose an unprecedented disease burden to patients, doctors and caregivers impacted by a group of conspicuous and heterogeneous group of 7000 indications, affecting a small number of individuals (< 1 in 2000) <sup>1</sup>. A recent report highlights that all rare diseases, when combined, affect one in 16 people worldwide <sup>2</sup>. An estimated 300 million people are affected worldwide with a rare disease, facing neglect and marginalization, particularly in low- and middle-income countries. Roughly 80% of these diseases are genetically predisposed <sup>3</sup>, with 70% showing an onset during childhood years <sup>4</sup>. However, 95% of these indications lack approved treatments, diagnosis takes an average of 4.8 years and 30% of the pediatric population die before age 5 <sup>1</sup>. The 2021 resolution of the United Nations (UN) on rare diseases highlights the need for improved access to healthcare, especially primary care, for the affected population and their families <sup>5</sup>. Whole-genome sequencing (WGS) along with improvement in several other genetic screening techniques hold promise for presymptomatic and more accurate diagnosis of rare diseases <sup>6</sup>. Next generation sequencing (NGS), non-invasive prenatal testing, carrier screening, advanced bioinformatics approaches for variant identification have been some of the key approaches applied <sup>7</sup>. Non coding DNA sequencing by WGS with these advancements can lead to earlier diagnoses, allowing for preventative measures, targeted therapies, and potentially improved outcomes <sup>8</sup>. High sensitivity and specificity for diagnosing rare neurological disorders have been demonstrated in this retrospective diagnostic accuracy study <sup>9</sup>. Integrated multi omics approaches have been shown to speed the diagnosis timeline in synergy with traditional methods <sup>10</sup>. Early diagnosis is crucial for improved health outcomes and quality of life, reducing treatment costs and ease financial hardships. The limited market potential for rare disease drugs discourages pharmaceutical development. Policies like the 1983 US Orphan Drug Act <sup>11</sup> incentivize orphan drug development, leading to hundreds of approved drugs globally. Novel therapeutic strategies like gene therapy offer hope, but accessibility remains a major hurdle. Treatments like Hemgenix <sup>12</sup>, Zynteglo <sup>13</sup> are exorbitantly expensive, reflecting the affordability crisis. Rare diseases often require specialized treatments available only in high-income countries, forcing some patients to pursue unaffordable medical tourism <sup>14</sup>. Parents of the pediatric population and caregivers face substantial burdens, including limited information, reduced

treatment options, financial strain, and potential career sacrifices<sup>15</sup>. Additionally, rare diseases can lead to social stigma due to lack of awareness, visible symptoms, and inadequate support from institutions like schools and workplaces. Despite recent advancements, rare diseases continue to pose significant challenges. Prioritizing early diagnosis, effective treatment, and increased research funding through specific policies<sup>16</sup> is crucial. A multifaceted approach integrating rare diseases into healthcare systems, addressing mental health considerations, and raising awareness is essential for progress and meeting the unmet needs of this population.

This study explores the therapeutic interventions' landscape against rare diseases taking into consideration 211 drugs approved by the European Medicines agency (EMA till 2021) for rare diseases or intended for rare disease use and drugs in developmental pipeline against rare diseases from 43 leading biopharmaceutical companies/biotech working in the space as shown in Table 1. The EMA approved drugs for rare diseases can be broadly classified into two segments, depending on designation status:

(1) Drugs with Orphan Drug Designation (ODD)<sup>17</sup>: These drugs received regulatory incentives and market exclusivity due to their specific development for rare diseases from EMA.

(2) Non-Orphan Drugs for Rare Diseases: Existing medications repositioned to treat rare conditions, potentially offering a faster route to patient and market access.

This expanding therapeutic landscape plays a crucial role in improving the cost of illness (COI) and quality of life (QoL) for millions of patients suffering from rare diseases in Europe. The revenue analysis encompasses the global market for these drugs. This comprehensive approach provides a broader understanding of the expanding landscape of these treatments both from a development and financial point of view. These meta analyses takes into account publicly available data sources like:

(1) Drug developmental Pipelines along with financial statements of major pharmaceutical and biotechnology companies (Table 1, Table 2) and

(2) European Medicines Agency (EMA) approved drugs information till 2021 (major present pharmaceutical assets) which ensures data integrity, coverage and facilitates future research endeavors (Table 3-6).

The market share for rare disease therapeutics are segmented based on:

(1) Pharma-Specific market shares: Examining the market position of pharmaceutical companies with these therapies.

(2) Disease-Specific market shares: Understanding the market proportions of the analyzed rare diseases targeted.

These additional segmentations provide deeper insights into the market dynamics of this realm, help in better understanding the market leaders and facilitate exploration of potential developmental cum market opportunities. By analyzing market segments, global revenue, and utilizing publicly available data, the study aims to concise, structure and analyze valuable knowledge of this evolving field. Ultimately, this research can pave the way for improved treatments and a brighter future for patients with rare diseases.

Interventions against rare diseases approved by the European Medicines Agency (EMA) have a global market of around 170 billion US dollars as of the fiscal year 2022-2023. There are around 597 unique interventions that were analyzed in this study, which consists of 211 approved interventions by EMA and 400 interventions that are in developmental pipelines of 43 different pharmaceutical players. The leaders of the market are Janssen Pharmaceuticals, Abbvie, Hoffmann-La Roche AG, Bristol-Myers Squibb, Vertex Pharmaceuticals and Novartis and this estimate aligns with the 2028 estimate of the leading pharmaceutical companies worldwide by projected orphan drug sales share <sup>18</sup>.

## Methods

### *Data sources:*

Data was extracted from publicly available information on company websites on developmental pipelines. The information on finances and market were derived from public information on company financial statements. All data sources and links are summarized on Table 1.

### *Meta analysis:*

A meta-analysis study was performed to elucidate the landscape of approved and in-development therapeutic interventions for rare diseases, taking into account the R&D pipelines of 176 biopharmaceutical companies/biotech (Table 1). Some of the key outputs analyzed in this study include the drug name, targeted disease, the mechanism of action of the interventions, therapy areas in which these interventions fall into, collaboration status and phase of clinical development. Furthermore, the geographical locations of the key players were analyzed to obtain a comprehensive view of the space.

The second study takes into account the approved interventions in the European region (EMA), with and without ODD status, and intended for usage in rare diseases. The annual financial reports (2023) of companies holding the market authorization of the interventions were analyzed for the product specific revenue, product specific percentage of market shares, indication specific market share distribution, company specific and disease area specific market share distribution (Table 3-7).

This multifaceted data analytics from the market shares and pipelines from companies help us to understand the therapeutic landscape and market dynamics in the rare disease realm.

### *Identification of interactions between indications and companies:*

To gain a collective understanding of how a company's developmental pipelines impact the R&D landscape for a specific rare disease and the therapeutic axes, we employed a bipartite network analysis. First, we constructed a network where companies are represented as nodes on one side. These company nodes were connected to two distinct sets of nodes on the other side. One set represented their collaborators, which are other companies the focal company works with (or

players that were acquired as a result of mergers and acquisitions). The third layer represented diseases currently under development by the focal company. This bipartite structure allows us to capture not only the company's research focus but also their collaborative landscape.

Next, we simulated the removal of individual companies from the network. This simulated the scenario of a company going out of business or exiting a particular research area. To assess the impact of this removal, we delved into the integrity of the remaining network, considering two key factors. Firstly, we quantified the total number of companies remaining that would actively remain in the specific disease of interest. Secondly, we analyzed the number of unique mechanisms of action (MoA) represented by the companies. By analyzing the diversity of MoA, we assessed the potential impact on the range of therapeutic approaches being explored for the disease. This combined measure offered a comprehensive picture of how a company's developmental pipelines affected both the overall research effort and the richness of approaches (MoA) for a particular disease (Table 8).

#### *Graphing and visualizations:*

Relationships among different parameters were plotted as a scatter-plot among different parameters such as market shares, revenues of highest selling assets, competitive index and collaborative index. Data was aggregated and collected in Microsoft Excel, with formatting performed using Excel functions such as *vlookup*. The plotting was done using Prism v10.2.3 (GraphPad) and custom-made scripts in the Python programming language. Figure panels were prepared in affinity designer and Inkscape softwares.

## Results

*Global map of pharmaceutical players, therapy areas of interventions and their corresponding mechanisms of action (MoA):*

The global distribution shows that the pharmaceutical entities involved in development and approval of drugs for rare diseases are headquartered mostly in first world countries. The United States is the leading location for the headquarters followed by European nations, Japan and Australia (Fig 1A, B). Some of the leading countries hosting these headquarters are the Netherlands, Germany, France, Ireland, Sweden, Italy, United Kingdom, Spain, Switzerland and Belgium (Fig 1C).




Figure 1: (A) Worldwide distribution of pharmaceutical entities having approved and in development therapeutics against rare diseases. (B) European distribution of pharmaceutical entities having approved and in development therapeutics against rare diseases. (C) Distribution of countries according to the number of pharmaceutical entities headquartered there.

The global leaders in therapy area distribution of the interventions against rare disease in development and approved are Targeted therapy, Enzyme replacement therapy (ERT), Gene therapy, Combinatorial therapy, antisense RNA therapy, CAR-T cell therapy and siRNA mediated interventions (Fig 2A). The mechanism of action landscape encompasses Enzyme Inhibitors (such as BTK inhibitors, TYK2 inhibitors, Transthyretin (TTR) inhibitors, UBE3A-ATS inhibitors, Bcl-2 inhibitors, VEGFR inhibitors and Factor D inhibitors), Activation Therapies (such as CFTR activators, orexin 2 receptor activators, and activators for receptors like the glucocorticoid receptor and GLP-2 receptor), Antibody-Based Therapies (such as anti-PD-1 antibodies, antibodies against type I interferon receptors, and antibodies targeting B cells like anti-CD20, antibodies against inflammatory mediators (anti-IL-6) and components of the complement system C5), Alternative Therapeutic Strategies such as recombinant human clotting factor VIII, DNA alkylating agents, CAR T-cell therapy targeting B-cell maturation antigen, and drugs that modulate cellular processes like protein translation (eIF2B activation) and fibrosis (TGF- $\beta$  inhibition) (Fig 2B). In the course of this landscape study, 641 rare disease interventions, 530 unique MoAs and 25 unique modalities were analyzed, along with individual pipeline analyses for the major players in rare diseases (Supplementary Fig 1, Supplementary Fig 2). Connectivity across parent companies sponsoring the development of an intervention, their collaboration and partnering with other companies/ biotechs and the disease shows that partnerships are key components of drug development in rare disease therapies (Fig 2C). Hoffmann-La Roche AG, Takeda, Abbvie, Biogen, Affinia therapeutics, Sarepta therapeutics. PTC therapeutics, Ionis pharmaceuticals, Astrazeneca AB, Spark therapeutics, PTC therapeutics, LogicBio therapeutics and Denali therapeutics lead in partnerships and collaborations in developmental pipelines (Fig 2D), in key therapeutic areas such as systemic lupus erythematosus (Novartis, Hoffmann-La Roche AG, Abbvie, Janssen, Astrazeneca and Bristol-Myers Squibb (including Celgene)), multiple myeloma (Ipsen Pharmaceuticals, Hoffmann-La Roche AG, Abbvie, Novartis, Janssen, Astrazeneca, Pfizer and Bristol-Myers Squibb), Duchenne muscular dystrophy (Hoffmann-La Roche AG, Vertex Pharmaceuticals, Ultragenyx, Affinia therapeutics, Sarepta therapeutics, Pfizer, PTC Therapeutics and Biomarin International), Amyotrophic lateral sclerosis (Biogen, Ionis Pharmaceuticals, Abbvie, PTC therapeutics, Alchemab therapeutics, Pharmanext and Denali



therapeutics), IgA Nephropathy (Hoffmann-La Roche AG, Alexion (part of Astrazeneca), Traverre therapeutics, Astrazeneca AB, Novartis and Takeda) and Spinal muscular atrophy (Hoffmann-La Roche AG, Novartis, Biogen, Ionis Pharmaceuticals and PTC therapeutics). All these players have single or multiple programs against the indications as represented by multiple occurrences of the pharmaceutical entities (Fig 2E). The drug development competitive landscape was further granulated using:

- (i) Single development: Only entity developing intervention against specific indications;
- (ii) Competitors: Multiple entities involved in therapeutic interventions development against the indication;
- (iii) Unique mechanism of action (MoA): Number of unique therapeutic axes used for therapeutic development from a mechanistic point of view and
- (iv) Shared MoAs: Number of shared therapeutic axes employed for therapeutic development from a mechanistic point of view.

It was revealed that Rocket pharmaceuticals, Sio Gene therapies, Sphero therapeutics and SpliceBio have a high degree of innovative index, but very low degree of competitive index. Companies like Sarepta Therapeutics, Bayer AG, Alchemy Therapeutics, Sumitomo Pharmaceuticals, Janssen, Biogen, Hoffmann-La Roche AG, PTC therapeutics, Vertex Pharmaceuticals, Ionis Pharmaceuticals, Affinia Therapeutics, Alexion (part of Astrazeneca AB) have a low degree of innovative index and a very high degree of competitive index, while Abbvie, Amgen, Genzyme (part of Sanofi), Astrazeneca AB, Orchard therapeutics, LogicBio Therapeutics have a comparable innovative and competitive index (Fig 2F). Furthermore, analyses of all the companies involved in therapeutic development in unique axes of MoAs yields biotech entities with high degree of innovative index or competitive index (either from disease perspective or MoA perspective) and are potentially key determinants for M&A activities (Fig 2F).



Figure 2: (A) Intervention specific therapy area distribution in the therapeutic landscape. (B) Intervention specific mechanism of action (MoA) distribution of the therapeutic landscape. (C) Connectivity matrix connecting the parent company, collaborative companies and the diseases targeted in their developmental pipeline. (D) Top pharmaceutical companies having the highest number of collaborations in their developmental pipelines. (E) Top 6 disease areas dominated by multiple pharmaceutical players increasing competitiveness. (F) Heatmap showing the innovative index and competitive index (disease and MoA) of different pharmaceutical players having developmental pipelines in rare disease space (Yellow: Highest; Blue: Lowest).

*Global distribution of EMA approved drugs (till 2021) with and without ODD status against rare indications having market shares:*

The European medicines agency (EMA) has approved interventions against 113 indications with ODD and 201 indications without ODD status till 2021. 13 of these indications (Multiple myeloma, Acute lymphoblastic leukemia, Type 1 Gaucher disease, Pulmonary arterial hypertension, Idiopathic Pulmonary fibrosis, Hereditary angioedema, Adrenal insufficiency, Chronic lymphocytic leukemia, Follicular lymphoma, Nephropathic cystinosis, Fabry disease, Cystic fibrosis and Haemophilia B) have interventions against them having both ODD and non-ODD status (Fig 3A). Out of the 400 interventions approved against rare diseases by EMA, 35% have ODD status while 65% do not have ODD status (Fig 3B). There has been a continuous increase in the number of drug approvals against rare disease with or without ODD status in the last few decades (Figure 3C, 3D). The EMA approved drugs having ODD against rare diseases are dominated by targeted therapy (71.5%) and enzyme replacement therapy (8.5%) (Fig 3E). Some of the key indications targeted by ODD drugs are Multiple myeloma, Cystic fibrosis, Spinal Muscular Atrophy, Endogenous cushing syndrome, hereditary angioedema and acute myeloid leukemia (Fig 3F). Novartis, Biogen International Limited, Janssen Cilag International, Hoffmann-La Roche AG, Celgene (acquired by Bristol-Myers Squibb), Pfizer, Alexion (Astrazeneca partner), Alnylam pharmaceuticals, Chiesi Pharmaceutical, Incyte Biosciences, Shire (part of Takeda), Takeda pharmaceuticals, Vertex pharmaceuticals, Advanced Accelerator Applications, Akcea Therapeutics, Amgen, Bayer AG, Bluebird bio, Genzyme (part of Sanofi) and Ipsen Pharmaceuticals are the key pharmaceutical players in this group (Fig 3G).

The EMA approved drugs against rare diseases without ODD status are dominated by targeted therapy (75.4%), enzyme replacement therapy (15.3%) and chemotherapy (4.8%) (Fig 3H). Some of the key indications targeted by non-ODD drugs are Multiple myeloma, Haemophilia A, Pleural mesothelioma, Cystic fibrosis and Acute lymphoblastic leukemia (Fig 3I). Pfizer, Merck, Novartis, Sandoz, Accord healthcare, Janssen International, Hoffmann-La Roche AG, Genzyme (part of Sanofi), Bayer AG, Eisai GmbH, Mylan SAS, Recordati Rare Diseases, Baxalta Innovations, Bristol Myers Squibb, Celgene (acquired by Bristol-Myers Squibb), CSL Behring, Novo Nordisk, Sanofi, Shire (part of Takeda) and Amgen remain key players in the non-ODD group (Fig 3J).




Figure 3: (A) Indications shared by EMA approved drugs for rare diseases with and without ODD. (B) Distribution of total number of EMA approved drugs having ODD and no ODD. (C) Approval timeline of drugs against rare diseases by EMA without ODD (1995-2021). (D) Approval timeline of drugs against rare diseases by EMA with ODD (2005-2021). (E) Therapy area distribution of drugs with ODD (n=130). (F) Cloud diagram showing the distribution of rare indications against which the ODD designated drugs were being approved (G) Top 20 pharmaceutical entities involved in this intervention space with ODD. (H) Therapy area distribution of drugs without ODD (n=268). (I) Cloud diagram showing the distribution of rare indications against which the non-ODD drugs were being approved (J) Top 20 pharmaceutical entities involved in this intervention space without ODD.

*Chemical network and mechanism of action driven landscape analysis of approved drugs against rare indications with and without ODD designation*

Drug-drug (red lines) and drug-protein (green lines) interaction networks represent the chemical landscape of the interventions. It shows that the drugs are quite discrete spatially which is due to the presence of innovative interventions targeting different biomarkers in the rare disease space which has received ODD (Fig 4A). Some of the key mechanisms of action represented by the ODD designated drugs are small molecule targeted therapy (such as CFTR activator, Transthyretin (TTR) inhibitor, Cysteine inhibitor, FXR inhibitor, TGF- $\beta$  inhibitor, 16S/23S rRNA inhibitor, 30S ribosomal protein S12 inhibitor, 5-HT<sub>2</sub> receptor agonist,  $\sigma$ <sub>1</sub> receptor inhibitor, ALAS1 inhibitor), antibody-mediated targeted therapy (such as Anti CD19 antibody, Anti IL6 antibody, Anti C5 antibody, Anti CCR4 antibody, Anti CD19/CD3 bispecific antibody, Anti FGF23 antibody, Anti CD20 antibody, Anti GD2 antibody, Anti PA (*B. anthracis* toxin) antibody, Anti plasma kallikrein antibody, Anti von Willebrand factor (vWF) antibody), antibody-drug conjugate (such as Anti CD30 antibody/monomethyl auristatin E (MMAE), Anti CD22 antibody/Calicheamicin, Anti CD33 antibody/Calicheamicin) and gene therapy (such as AAV mediated SERPINA1 gene transfer, AAV9 mediated SMN gene transfer, AAV mediated RPE65 gene transfer) (Fig 4B).

Similarly, drug-drug (red lines) and drug-protein (green lines) interaction networks among the non-ODD interventions might suggest that these interventions are mostly repositioned from other non-rare indications that share common targets and mechanisms of action (Fig 4C). The key mechanisms of action represented by the non-ODD designated drugs are small molecule targeted therapy, antibody mediated targeted therapy, enzyme replacement therapy and alternative therapies like DNA alkylating agent and Folate antimetabolites (Fig 4D).




Figure 4: (A) Chemical network represented by ODD designated interventions: drug-drug (red) and drug-protein (green) interaction framework. (B) Top 30 mechanisms of actions represented by interventions with ODD designation. (C) Chemical network represented by non ODD interventions: drug-drug (red) and drug-protein (green) interaction framework. (D) Top 30 mechanisms of actions represented by interventions without ODD designation.

*Market share landscape of therapeutic space against rare diseases with and without ODD status:*

A review of the pharmaceutical industry identified 20 key players by revenue and market share. Janssen (10.8%) topped the list, followed by Hoffmann-La Roche (9.6%) and AbbVie (9.1%).

Mergers and acquisitions are reflected, with Celgene (6.8%) included under Bristol-Myers Squibb and Alexion (4.2%) under AstraZeneca. The remaining companies include Vertex Pharmaceuticals (5.5%), Novartis (6.5%), Amgen (4.4%), Pfizer (4.4%), Merck (4.3%), CSL Behring (3.3%), Pharmaxis (2.4%), Genzyme (part of Sanofi, 2.2%), Boehringer Ingelheim (2.1%), Takeda (2.1%), Biogen (2.0%), BioMarin (1.3%), Eisai (1.1%), and Eli Lilly (1.0%) (Figure 5A, 5B). In addition, Amgen, Novartis, Hoffmann-La Roche AG, Pfizer, Biomarin international, Celgene (part of Bristol-Myers Squibb) Genzyme (part of Sanofi), Janssen, Merck, Recordati Rare Diseases, Sandoz, Takeda, Bristols-Myers Squibb, Alexion (part of Astrazeneca), Bayer AG, Biogen, CSL Behring, Eli Lilly, Vertex Pharmaceuticals Abbvie and Alnylam Pharmaceuticals also boasts of a large number of pharmaceutical portfolio of assets under their belts (Fig 5C). The market leaders of this therapeutic space were estimated using a correlation study between the total revenue and the highest grossing asset of each of the companies. It showed that there are three separate divisions among the players: The Market leaders (6-12%): Janssen, Abbvie, Hoffmann-La Roche AG and Novartis and Celgene (part of Bristol-Myers Squibb); The upcoming major players (2.5-6%): Vertex pharmaceuticals, Bristol-Myers Squibb non-Celgene portfolio, Pfizer, Amgen, Merck, Alexion (part of Astrazeneca), CSL Behring and Astrazeneca AB non-Alexion portfolio; The Challengers to the market space (<2.5%): Pharmaxis, Boehringer Ingelheim, Takeda, Biogen, Genzyme (part of Sanofi), Bayer AG and Alnylam Pharmaceuticals among others (Fig 5D). Physiological system specific company distribution of assets were analyzed and it provides the granularity of the number of interventions in correlation to the body system their targeted indications affect. A further analysis by the organ system unveiled a diverse distribution of interventions. Several companies, like AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, Roche, and Sandoz focus their efforts with a single intervention specific to the complex Liver/Heart/Lung or the broader Reproduction/Lung/Stomach/Gut/Skin systems. Similarly, companies like Amgen, Bristol-Myers Squibb, Janssen, and Sanofi hold a single intervention in the Kidney/Blood/Gut/Bone space, suggesting a more targeted approach in these areas. However, the landscape shifts when examining companies with multiple interventions within specific organ systems. Here, we see a more concentrated focus. For example, Janssen and Eli Lilly take a leading role in the Lung system with two and three interventions, respectively.

Similarly, Bayer AG, Recordati Rare Diseases, and Amgen (among others) hold multiple assets in the Blood and Liver systems, indicating a strategic investment in these critical areas. This trend highlights the varied approaches companies take when developing interventions, with some opting for a broader reach and others focusing on specific organ systems with multiple offerings (Fig 5E). A scatter plot between the total market share of the pharmaceutical entities in rare therapeutics space and their total assets in pipeline shared by other competitors gives an estimate of the market leaders in two perspectives: Approved drugs in market and drug development in a competitive environment (Fig 5D). Janssen, Hoffmann-La Roche AG and Novartis are the leaders having the highest market shares and richest developmental pipeline in the competitive disease environment (Competitive index closer to 1). Market leaders like Abbvie have a high share of the market space but play in a lower risk environment (Competitive index close to 0.5). The upcoming players like Vertex Pharmaceuticals, Bristol Myers Squibb (including Celgene developmental portfolio), Pfizer and Alexion (part of Astrazeneca AB) have median market shares and also are a part of a highly competitive disease landscape (Competitive index closer to 1). Amgen and Astrazeneca (without Alexion portfolio) have median market percentages but work in diseases which are shared to a lesser extent among the competitors (Competitive index closer to 0.5). Challengers like Biogen, Bayer AG and PTC therapeutics play in a strong competitive position (Competitive index closer to 1), but have comparatively less market shares than its competitors. Entities like Genzyme (part of Sanofi), Takeda, Biomarin Pharmaceuticals, Ipsen Pharmaceuticals, Ultragenyx and Orchard therapeutics are working in therapeutic areas which can accommodate higher levels of competition (Competitive index closer to 0.5) and thus even their market shares are less, they have opportunities to expand their market positioning (Fig 5F). Talking about the perspective of unique mechanism of actions that the interventions follow against the diseases in developmental pipeline, all the prominent market players like Vertex Pharmaceuticals, Hoffmann-La Roche AG, Abbvie, Takeda Novartis, Bristol-Myers Squibb (including Celgene portfolio), Amgen, Pfizer, Astrazeneca AB, Genzyme, Biomarin International have a very high innovation index (close to 1) and are distributed across the entire market share landscape (high to low). Entities like Janssen, Alexion (part of Astrazeneca AB), Biogen, PTC



Therapeutics cover are distributed in the market share landscape having relatively lower innovation index (close to 0.5) (Fig 5G).




Figure 5: (A) Revenue distribution among the pharmaceutical entities (in million dollars) in rare disease space. (B) Rare disease therapeutic market share distribution among the pharmaceutical entities (percentage). (C) Top 20 pharmaceutical companies having the highest number of money making assets (D) Market leader estimation using the corresponding correlation coefficients between the total revenue and highest grossing asset. (E) Physiological system specific company distribution of assets. (F) Scatter plot showing the competitive index for disease space targeted by the pharmaceutical players (developmental pipelines) in perspective to the total market shares (approved drugs). (G) Scatter plot showing the innovative index driven by unique MoAs targeted by the pharmaceutical players (developmental pipelines) in perspective to the total market shares (approved drugs).

*Market share landscape of disease and system specific therapeutics against rare diseases:*

Disease specific market share analysis was performed taking into account the total revenues of multiple drugs against the indications. A bubble diagram has been employed to visualize the relationships which shows the top diseases having the highest value making assets: Cystic fibrosis, Multiple myeloma, Polyarticular juvenile idiopathic arthritis, Renal cell carcinoma, Haemophilia A, Spinal muscular atrophy and Chronic lymphocytic leukemia (Fig 6A) A physiological system (single or multi system) specific market share analysis takes into account the total cash flow from interventions targeting the diseases affecting the specific physiological systems which has been represented by a radial map (Scale: Blue: Highest market share; Brown: Lowest market share) (Fig 6B). The top organ systems having the highest pharmaceutical assets are Liver/Heart/Lung, Reproduction/Lung/Stomach/Gut/Skin, Kidney/Blood/Gut/Bone, Lung, Kidney, Blood, Musculoskeletal system, Lung/Liver/Bone, Blood/Bone, Lung/Liver/Bone/Kidney, Kidney/Blood/Gut/Bone/Liver, Reproduction, Liver and Heart (Fig 6C).




Figure 6: (A) Disease specific market share analysis of approved interventions (EMA) in rare disease therapeutics space. (B) Radial map showing disease and organ specific market share analysis (Blue: Highest; Brown: Lowest) of approved rare disease therapeutics in the EMA. (C) Top disease specific organ systems targeted by EMA approved drugs in context of market shares.

## Discussion

For those living with a rare disease, the world can feel like a vast, uncharted territory. The challenges are immense - limited treatment options, a lack of awareness, and the constant struggle to find answers. But amidst this landscape, a beacon of hope is emerging as recent research has shed light on the global efforts to combat these complex conditions, revealing a dynamic field brimming with innovation and promise. The study paints a picture of a global crusade against rare disease where pharmaceutical giants in the United States, Europe, Japan, and Australia are leading the charge, leveraging their expertise and resources to develop life-changing therapies. This international collaboration is crucial, as rare diseases often transcend geographical boundaries. By pooling resources and sharing knowledge, researchers are accelerating the pace of discovery, bringing much-needed hope to patients worldwide. The research delves deeper, unveiling the specific "weapons" employed in this fight. Targeted therapies take center stage, emerging as the most dominant approach - and for good reason. These therapies are exquisitely precise interventions, honing in on the specific biological pathways that underlie rare diseases <sup>19</sup>. Unlike traditional medications with broader applications, targeted therapies offer a more potent and well-tolerated approach. This focus on precision medicine represents a significant leap forward in the battle against rare diseases <sup>20</sup>. While targeted therapies stand as the leading force, the arsenal against rarity doesn't stop there. Enzyme replacement therapies <sup>21</sup>, for instance, offer a lifeline for patients with conditions caused by missing or dysfunctional enzymes. Similar to a missing cog in a complex machine – enzyme replacement therapies act like replacement parts, restoring functionality and alleviating symptoms. Gene therapy also holds immense promise in targeting specific genetic predispositions responsible for the indications <sup>22</sup>. This modality tackles the root cause of some rare diseases by introducing healthy copies of defective genes directly into a patient's cells. While still in its early stages, gene therapy has the potential to offer permanent cures for a range of rare conditions. The therapeutic landscape further differentiates between drugs with and without Orphan Drug Designation (ODD) <sup>17</sup>. ODD status is awarded to drugs specifically developed for rare diseases, incentivizing research and development in this underserved field. The analysis reveals a fascinating distinction between these two categories. ODD drugs form a more distinct

network of interactions, suggesting they target unique biological pathways not addressed by existing medications. This signifies the cutting-edge nature of ODD drugs – they represent the frontiers of rare disease research, venturing into uncharted territory to find groundbreaking solutions. The concept of a drug-protein network provides a compelling way to visualize the intricate interplay between medications and the human body. The stronger the interaction between a drug and a protein, the thicker the connecting line. In the case of ODD drugs, these networks appear more discrete, showcasing their unique targeting mechanisms while for non-ODD drugs, it's more dense, connected and populated revealing the life cycle management (LCM) and drug repositioning opportunities <sup>23</sup>. While scientific innovation holds the key to unlocking new treatment options, the commercial landscape plays a critical role in ensuring these therapies reach the patients who need them most. This study delves into the world of market share, revealing the pharmaceutical giants who are leading the charge in terms of revenue generated. Companies like Janssen, Roche, AbbVie, Bristol-Myers Squibb and Novartis are at the forefront, demonstrating their commitment to rare disease research and development. However, the landscape is not static. Emerging players like Amgen and Vertex Pharmaceuticals are making significant strides, bringing fresh perspectives and innovative approaches to the table. This healthy competition is a positive sign for patients, as it fuels the development of even more effective therapies. The increasing number of players also suggests a growing awareness of the importance of this field, paving the way for a brighter future for patients with rare diseases. The relentless pursuit of knowledge regarding rare diseases holds the promise of groundbreaking discoveries. One exciting possibility lies in precision medicine <sup>24</sup>, where targeted therapies are becoming even more granular <sup>25</sup>. Researchers envision tailoring therapies to the unique genetic fingerprint of each patient or patient group <sup>26</sup>. This personalized approach promises to maximize efficacy, minimize side effects, and usher in a new era of individualized treatment. Additionally, gene therapy advancements like CRISPR <sup>27-29</sup>, AAV-mediated therapies <sup>30-32</sup>, and antisense oligonucleotide approaches <sup>33,34</sup> offer the potential for permanent cures through precise genetic code editing. Finally, the vast amount of data generated by research presents a unique opportunity <sup>35</sup>. By harnessing the power of big data analytics, researchers can identify hidden patterns and connections, accelerating drug discovery and our understanding of rare diseases <sup>36</sup>.

While the future looks promising, there are still hurdles to overcome. One of the biggest challenges is ensuring equitable access to these life-changing therapies<sup>37</sup>. The high cost of rare disease medications can be a significant barrier for patients<sup>38,39</sup>. Collaborative efforts between researchers, pharmaceutical companies, and policymakers are crucial to bridge this gap and ensure that everyone has the opportunity to benefit from these advancements. The landscape of rare disease research is no longer a desolate wasteland but a vibrant ecosystem teeming with innovation and collaboration. Researchers are wielding a diverse range of therapeutic approaches, from targeted therapies to gene therapy, while pharmaceutical giants and rising stars jostle for market share, pushing the boundaries of science. Ultimately, this dynamic environment offers a glimmer of hope for patients and their families, paving the way for a future where rare diseases are no longer a life sentence, but a challenge with a solution within sight. In the face of a healthcare crisis for millions, philanthropic funding stands as a power of progress for those living with rare diseases. Unlike traditional pharmaceutical companies whose focus is on maximizing profits, philanthropic organizations like rare disease dedicated foundations<sup>40-42</sup> and private philanthropists<sup>43</sup> bridge the critical gap between the exorbitant costs of research and development and the limited market size associated with rare diseases. This allows for crucial early-stage research that might otherwise be left unexplored, potentially leading to groundbreaking discoveries. Philanthropic activities have guided development of the state of the art care against multiple cancer types in the USA led by healthcare centers like Dana Farber Cancer research Institute, MD Anderson comprehensive cancer center and Sidney Kimmel comprehensive cancer center<sup>44-46</sup>. These hospitals and cancer centers today, being some of the best healthcare centers worldwide for oncologic indications, all started in the last century when philanthropy paved the way to increased research, large scale patient care and access. It is opined that rare disease should follow a similar trajectory. Furthermore, philanthropic funders are driven by a mission of alleviating human suffering, not just financial gain. This patient-centric approach allows them to champion research on diseases affecting smaller populations, a demographic often overlooked by for-profit entities. This commitment to patient well-being extends beyond just funding. Philanthropic organizations can also play a vital role in fostering innovation by supporting smaller research institutions and companies with promising ideas that

might not fit the traditional model. By providing crucial financial resources and fostering collaboration, philanthropic funding acts as a catalyst, accelerating the development pipeline and bringing life-changing treatments closer to the millions living with the daily challenges of rare diseases. There have been recent advancements in the EU pharmaceutical reforms <sup>16</sup> where Members of the European Parliament (MEPS) have adopted proposals for sweeping reforms to EU pharmaceutical legislation, aiming to stimulate innovation while improving drug accessibility and affordability. Rare and chronic diseases are the key areas of focus. The European Union (EU) has proposed a comprehensive strategy to address the challenges of rare diseases. This initiative prioritizes ensuring the development and availability of high-quality, safe, and effective treatments for all EU patients with rare diseases. Equitable access to these treatments across all member states is a key focus, aiming to remove geographical barriers. Additionally, the proposal emphasizes the importance of a secure supply chain to guarantee uninterrupted patient access to these potentially life-saving therapies. Finally, fostering a robust research environment is envisioned to stimulate the continuous development of novel treatments for this complex group of diseases. The proposal aims to target some of the important shortcomings in the present rare pharmaceutical legislation:

- (1) Patients' unmet medical needs with rare diseases and of children are consistent.
- (2) Health systems face significant challenges in coping up with the exorbitant price-tags of the medications.
- (3) Patient access to rare disease medications through the EU is incoherent.
- (4) Regulatory hurdles serve as a roadblock in many cases leading to increased delay in patient access.

The European Union is aiming to simplify its regulations for all medicines by merging specific rules for rare disease and pediatric treatments into a single, more coherent framework. Importantly, this change won't affect the high quality, safety, and effectiveness standards for these specialized medicines as they will still follow the same rigorous approval process as any other

medication. However, the new regulations will recognize the unique challenges of developing treatments for rare diseases and children. Unlike medications for common illnesses, market forces alone don't create enough incentive for research in these areas. Therefore, the revised regulations will maintain specific requirements that provide additional support for this crucial research. This ensures continued development of new and effective treatments for these often-overlooked patient populations. To ensure the best outcome for revising rare disease and children's medicine regulations, a comprehensive analysis was conducted. This included examining three different policy directions (A, B, and C) for each regulation. They are as follows: Option A: Maintains 10-year exclusivity plus adds a transferable voucher for high unmet medical need (HUMN) products. This voucher grants a 1-year extension or can be sold for use on another product. Option B: Eliminates the current 10-year exclusivity for all rare disease treatments. Option C: Offers variable exclusivity (5, 9 or 10 years) based on the type of treatment (established use, new drug and HUMN respectively). An additional one-year extension is possible for HUMN and new drug products based on patient access across the EU. Following a comprehensive evaluation of the specific objectives and potential economic and social impacts, Option C emerged as the preferred policy choice. It strikes a balance between all four revision goals, promoting investment and innovation, especially for high unmet medical need (HUMN) treatments. This won't hinder the development of other rare disease drugs. Additionally, Option C is expected to (i) boost EU pharmaceutical competitiveness, including small and medium-sized enterprises (SMEs), (ii) improve patient access to medicines through earlier entry for generic and biosimilar drugs and (iii) reduce administrative burdens and better accommodate new technologies with more flexible criteria for defining orphan diseases. The proposed revisions target core procedures required for market authorization of medicines and their life cycle management activities resulting in a streamlined regulatory framework with improved efficiency, effectiveness and access <sup>47</sup>.

Patients associations are crucial for raising awareness against rare diseases <sup>48,49</sup>. Rare diseases for obvious reasons are not well known by the common people due to their meager incidence rates. Patient associations can take up initiatives to educate people leading to higher awareness among people and increased focus among healthcare experts as well as policymakers for rare



disease treatments. Thus they play a vital role in driving the remission of the high unmet needs that rare diseases bring with them. In addition to that, patients associations contribute substantially to funding and research against rare diseases driven by non-profit organizations, biotech SMEs and big pharmaceutical entities <sup>50</sup>. Diving more into details, clinical trials play a major role in therapeutic development against any kind of indications. On top of that, patient identification and enrollment for clinical trials targeting rare diseases is more challenging which is explained by the low number of volunteers for orphan drug development, however, it is still challenging for the eligibility criteria to be entirely met. Patients association helps considerably in solving this issue by connecting clinical researchers working on clinical trials to specific and marginalized patient populations. This facilitates successful development of the intervention and expanded patient access. Successful collaborations between patient associations and clinical researchers (CT sponsors) can help in better elucidation of the high unmet needs of patients suffering from rare diseases and their caregivers. These kind of extensive partnerships would help in optimization of patient experiences participating in targeted clinical trials which has the potential to improve patient quality of life (QoL) significantly by improvement of the standard of care treatments <sup>51,52</sup>.

### **Limitations of this study**

This study has two potential limitations. First, being an EU perspective of the rare disease therapeutics landscape, it includes only the EMA approved drugs and not the FDA approvals. However, the expanded intervention picture is a future scope of study. Second, some approved interventions have multifaceted disease targets, both rare and non-rare. This might have led to some overlapping market shares from non-rare diseases being incorporated in the total market size estimation for the EMA approved rare disease therapeutics.

## **Declaration of interests**

All authors declare they have no competing interests.

## **Acknowledgements**

We thank Dr. Pierre-Axel Monternier and Mr. Victor Hannotiaux for reading the manuscript and providing critical feedback.

## **Author Contributions**

Conceptualization: SS, MS

Methodology: MS, EC

Investigation: MS, EC

Visualization: NBL, DM

Supervision: SS

Writing—original draft: SS, MS, EC

Writing—review & editing: SS, MS, EC, NBL, DM

## **Data and materials availability**

All data are available in the main text or the supplementary materials.

## References

- 1 The Lancet Global Health. The landscape for rare diseases in 2024. *The Lancet Global Health* 2024; **12**: e341.
- 2 Pollard S, Weymann D, Dunne J, *et al*. Toward the diagnosis of rare childhood genetic diseases: what do parents value most? *Eur J Hum Genet* 2021; **29**: 1491–501.
- 3 Rare diseases - European Commission. [https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases\\_en](https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en) (accessed July 21, 2024).
- 4 What is a rare disease? EURORDIS. <https://www.eurordis.org/information-support/what-is-a-rare-disease/> (accessed July 21, 2024).
- 5 UN Resolution on Persons Living with a Rare Disease and their Families. <https://www.rarediseasesinternational.org/wp-content/uploads/2022/01/Final-UN-Text-UN-Resolution-on-Persons-Living-with-a-Rare-Disease-and-their-Families.pdf> (accessed July 21, 2024).
- 6 Vockley J, Aartsma-Rus A, Cohen JL, *et al*. Whole-genome sequencing holds the key to the success of gene-targeted therapies. *American J of Med Genetics Pt C* 2023; **193**: 19–29.
- 7 Yang X-A, Hao H, Liao C. Editorial: Next generation sequencing (NGS) for rare diseases diagnosis - Volume II. *Front Genet* 2023; **14**: 1249585.
- 8 Brlek P, Bulić L, Bračić M, *et al*. Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives. *Cells* 2024; **13**: 504.
- 9 Ibañez K, Polke J, Hagelstrom RT, *et al*. Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study. *Lancet Neurol* 2022; **21**: 234–45.
- 10 Lunke S, Bouffler SE, Patel CV, *et al*. Integrated multi-omics for rapid rare disease diagnosis on a national scale. *Nat Med* 2023; **29**: 1681–91.
- 11 Orphan drug Act 1983. <https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf> (accessed July 21, 2024).
- 12 Cohen J. Despite Eye-Popping \$3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small. Forbes. <https://www.forbes.com/sites/joshuacohen/2022/12/02/despite-eye-popping-35-million-price-tag-for-gene-therapy-hemgenix-budget-impact-for-most-payers-will-be-relatively-small/> (accessed July 21, 2024).
- 13 The Most Expensive Drug in the US is a Rare-Disease Game Changer - Bloomberg. <https://www.bloomberg.com/news/newsletters/2022-08-24/the-most-expensive-drug-in-the-us-is-a-rare-disease-game-changer> (accessed July 21, 2024).
- 14 Skweres-Kuchta M, Czerska I, Szaruga E. Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective. *IJERPH* 2023; **20**: 2483.

- 15 Brandt M, Johannsen L, Inhestern L, Bergelt C. Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs. *Orphanet J Rare Dis* 2022; **17**: 274.
- 16 Parliament adopts its position on EU pharmaceutical reform | News | European Parliament. 2024; published online April 10. <https://www.europarl.europa.eu/news/en/press-room/20240408IPR20308/parliament-adopts-its-position-on-eu-pharmaceutical-reform> (accessed July 21, 2024).
- 17 Orphan designation: Overview | European Medicines Agency. <https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview> (accessed July 21, 2024).
- 18 Sales share from orphan drug by top companies 2028 forecast. Statista. <https://www.statista.com/statistics/373373/top-companies-based-on-global-orphan-drug-sales-share/> (accessed July 21, 2024).
- 19 Ehrhart F, Willighagen EL, Kutmon M, Van Hoften M, Curfs LMG, Evelo CT. A resource to explore the discovery of rare diseases and their causative genes. *Sci Data* 2021; **8**: 124.
- 20 Might M, Crouse AB. Why rare disease needs precision medicine—and precision medicine needs rare disease. *Cell Reports Medicine* 2022; **3**: 100530.
- 21 Marchetti M, Faggiano S, Mozzarelli A. Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency. *CMC* 2022; **29**: 489–525.
- 22 Gene therapy for rare diseases. *Nat Genet* 1999; **22**: 313–4.
- 23 Roessler HI, Knoers NVAM, Van Haelst MM, Van Haaften G. Drug Repurposing for Rare Diseases. *Trends in Pharmacological Sciences* 2021; **42**: 255–67.
- 24 Villalón-García I, Álvarez-Córdoba M, Suárez-Rivero JM, *et al.* Precision Medicine in Rare Diseases. *Diseases* 2020; **8**: 42.
- 25 Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. *Nat Rev Drug Discov* 2023; **22**: 101–26.
- 26 Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. *Fertility and Sterility* 2018; **109**: 952–63.
- 27 Chavez M, Chen X, Finn PB, Qi LS. Advances in CRISPR therapeutics. *Nat Rev Nephrol* 2023; **19**: 9–22.
- 28 Li Q, Gao Y, Wang H. CRISPR-Based Tools for Fighting Rare Diseases. *Life* 2022; **12**: 1968.
- 29 Papisavva P, Kleanthous M, Lederer CW. Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases. *Mol Diagn Ther* 2019; **23**: 201–22.
- 30 Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. *Front Med* 2022; **8**: 809118.

- 31 Lin C, Greenblatt MB, Gao G, Shim J-H. Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases. *Human Gene Therapy* 2024; **35**: 317–28.
- 32 Hastie E, Samulski RJ. Recombinant adeno-associated virus vectors in the treatment of rare diseases. *Expert Opinion on Orphan Drugs* 2015; **3**: 675–89.
- 33 Lauffer MC, Van Roon-Mom W, Aartsma-Rus A, N = 1 Collaborative. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. *Commun Med* 2024; **4**: 6.
- 34 Chen X, Birey F, Li M-Y, *et al*. Antisense oligonucleotide therapeutic approach for Timothy syndrome. *Nature* 2024; **628**: 818–25.
- 35 Park J-B. Using Big Data to Understand Rare Diseases. *Int J Heart Fail* 2021; **3**: 194.
- 36 Wojtara M, Rana E, Rahman T, Khanna P, Singh H. Artificial intelligence in rare disease diagnosis and treatment. *Clinical Translational Sci* 2023; **16**: 2106–11.
- 37 Adachi T, El-Hattab AW, Jain R, *et al*. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. *IJERPH* 2023; **20**: 4732.
- 38 Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. Disentangling the Cost of Orphan Drugs Marketed in the United States. *Healthcare* 2023; **11**: 558.
- 39 Liu A. Ultra-rare disease specialists top 2021's pricey drugs list, but Takeda, Merck KGaA meds rank, too | Fierce Pharma. 2021; published online March 9. <https://www.fiercepharma.com/pharma/ultrarare-disease-drug-ascends-to-top-most-expensive-pharmacy-drugs-u-s-2021> (accessed July 21, 2024).
- 40 Rare Diseases International Rare Diseases International. Rare Diseases International. 2024; published online July 21. <https://www.rarediseasesinternational.org/> (accessed July 21, 2024).
- 41 Home | BLACKSWAN Foundation. <https://www.blackswanfoundation.ch/en/> (accessed July 21, 2024).
- 42 Financial Support. EveryLife Foundation for Rare Diseases. <https://everylifefoundation.org/financial-support/> (accessed July 21, 2024).
- 43 Philanthropy in Europe April 2015.pdf. [https://www.fondationdefrance.org/images/pdf/Philanthropy\\_in\\_Europe\\_april\\_2015.pdf](https://www.fondationdefrance.org/images/pdf/Philanthropy_in_Europe_april_2015.pdf) (accessed July 21, 2024).
- 44 Milestones in the History of Dana-Farber and the Jimmy Fund | Dana-Farber Cancer Institute. <https://www.dana-farber.org/about/history/timeline> (accessed July 21, 2024).
- 45 Fueled by philanthropy | MD Anderson Cancer Center. <https://www.mdanderson.org/publications/promise/fueled-by-philanthropy.h34-1589046.html> (accessed July 21, 2024).

- 46 Our History- Johns Hopkins. <https://www.hopkinsmedicine.org/kimmel-cancer-center/our-history> (accessed July 21, 2024).
- 47 Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52023PC0192> (accessed July 21, 2024).
- 48 National Organization for Rare Disorders | NORD. 2022; published online March 8. <https://rarediseases.org/> (accessed July 21, 2024).
- 49 European Patient Advocacy Groups (ePAGs). EURORDIS. <https://www.eurordis.org/our-priorities/european-reference-networks/epag/> (accessed July 21, 2024).
- 50 Gentilini A, Miraldo M. The role of patient organisations in research and development: Evidence from rare diseases. *Social Science & Medicine* 2023; **338**: 116332.
- 51 Roennow A, Sauvé M, Welling J, *et al.* Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations. *BMJ Open* 2020; **10**: e039473.
- 52 Lopes-Júnior LC, Ferraz VEF, Lima RAG, *et al.* Health Policies for Rare Disease Patients: A Scoping Review. *IJERPH* 2022; **19**: 15174.

## Tables

Table 1: List of data sources used in the report.

Table 2: Distribution of pharmaceutical players and biotech across the world.

Table 3: List of drugs and interventions analyzed in the present study.

Table 4: List of drugs in development by companies and segregated by indications and MoA.

Table 5: Landscape of rare disease therapeutics having orphan drug designation.


Table 6: Landscape of rare disease therapeutics having non-orphan drug designation.

Table 7: Revenue and market share landscape for the interventions analyzed.

Table 8: List of developmental pipelines across pharma companies with the largest market shares in rare diseases.


## Supplementary materials




### Supplementary Fig 1












## Supplementary Fig 2



**A****B****C**




### A Indications shared by ODD and non ODD drugs approved by the EMA




Multiple myeloma  
Acute lymphoblastic leukaemia  
Acute myeloid leukaemia  
Type 1 Gaucher disease  
Pulmonary arterial hypertension  
Idiopathic Pulmonary Fibrosis  
Hereditary angioedema  
Adrenal insufficiency  
Chronic lymphocytic leukaemia/  
Follicular lymphoma  
Nephropathic cystinosis  
Fabry disease  
Cystic fibrosis  
Haemophilia B


Total=400




### C Number of drugs approved by the EMA: Including Non-ODD




### D Number of drugs approved by the EMA: Including ODD




### Drugs approved by the EMA having ODD status



### G Top 20 entities




### E




Total number of drugs = 130




### Drugs approved by the EMA having non-ODD status



### J Top 20 entities



### H




Total number of drugs = 268




**A**


Chemical network represented by ODD drugs: drug drug interactions (red) and drug protein interactions (green)

**B**

Top 30 MoAs represented by the ODD drugs

**C**

Chemical network represented by non-ODD drugs: drug drug interactions (red) and drug protein interactions (green)

**D**

Top 30 MoAs represented by the non-ODD drugs

